{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T23:42:38Z","timestamp":1770680558432,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,8]]},"DOI":"10.7759\/cureus.103240","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T06:10:37Z","timestamp":1770617437000},"source":"Crossref","is-referenced-by-count":0,"title":["The Analytical Performance and Inter-laboratory Standardization of Next-Generation Sequencing (NGS) Panels for Genetic Risk Stratification in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Ayman","family":"Alqurain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leen F","family":"Mashat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najwa M","family":"Alshammari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hashim A","family":"AL-Sumaily","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alqasem M","family":"Alamer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reem S","family":"Aldhmadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muzun D","family":"Albalawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nada S","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali S","family":"Metwaly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil E","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, et al.. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016, 374:2209-21. 10.1056\/NEJMoa1516192","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-020-00674-7","article-title":"Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies","volume":"27","author":"Hou HA","year":"2020","unstructured":"Hou HA, Tien HF. Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies. J Biomed Sci. 2020, 27:81. 10.1186\/s12929-020-00674-7","journal-title":"J Biomed Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.2208","article-title":"Genomics of acute myeloid leukemia diagnosis and pathways","volume":"35","author":"Bullinger L","year":"2017","unstructured":"Bullinger L, D\u00f6hner K, D\u00f6hner H. Genomics of acute myeloid leukemia diagnosis and pathways. J Clin Oncol. 2017, 35:934-46. 10.1200\/JCO.2016.71.2208","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-99-3810-0_5","article-title":"Genomic landscape and risk stratification of acute myeloid leukemia","author":"Hou HA","year":"2023","unstructured":"Hou HA. Genomic landscape and risk stratification of acute myeloid leukemia. Pathogenesis and Treatment of Leukemia. Gill H, Kwong YL (ed): Springer Nature Singapore, Singapore; 2023. 61-98. 10.1007\/978-981-99-3810-0_5"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner H","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, et al.. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017, 129:424-47. 10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner H","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, et al.. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022, 140:1345-77. 10.1182\/blood.2022016867","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-75810-2_2","article-title":"Acute myeloid leukemia risk stratification","author":"Zhang L","year":"2024","unstructured":"Zhang L. Acute myeloid leukemia risk stratification. Consulting Hematology and Oncology Handbook. Rivero G, Sosa IR (ed): Springer Nature Switzerland, Cham; 2024. 19-23. 10.1007\/978-3-031-75810-2_2"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser M","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, et al.. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021, 138:2753-67. 10.1182\/blood.2021013626","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis GJ","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S, et al.. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018, 131:1275-91. 10.1182\/blood-2017-09-801498","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-00765-5","article-title":"Treatment of relapsed acute myeloid leukemia","volume":"21","author":"Thol F","year":"2020","unstructured":"Thol F, Ganser A. Treatment of relapsed acute myeloid leukemia. Curr Treat Options Oncol. 2020, 21:66. 10.1007\/s11864-020-00765-5","journal-title":"Curr Treat Options Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2626","article-title":"Sequencing technologies - the next generation","volume":"11","author":"Metzker ML","year":"2010","unstructured":"Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet. 2010, 11:31-46. 10.1038\/nrg2626","journal-title":"Nat Rev Genet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024534","article-title":"Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers","volume":"384","author":"Duncavage EJ","year":"2021","unstructured":"Duncavage EJ, Schroeder MC, O'Laughlin M, et al.. Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers. N Engl J Med. 2021, 384:924-35. 10.1056\/NEJMoa2024534","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis ER","year":"2009","unstructured":"Mardis ER, Ding L, Dooling DJ, et al.. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009, 361:1058-66. 10.1056\/NEJMoa0903840","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel JP","year":"2012","unstructured":"Patel JP, G\u00f6nen M, Figueroa ME, et al.. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012, 366:1079-89. 10.1056\/NEJMoa1112304","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2024-4628","article-title":"Validation of an automated, scalable comprehensive genomic profiling assay for hematologic malignancies","volume":"84","author":"Hogg G","year":"2024","unstructured":"Hogg G, Liu T, Cao H, et al.. Validation of an automated, scalable comprehensive genomic profiling assay for hematologic malignancies. Cancer Res. 2024, 84:4628. 10.1158\/1538-7445.am2024-4628","journal-title":"Cancer Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting PF","year":"2011","unstructured":"Whiting PF, Rutjes AW, Westwood ME, et al.. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011, 155:529-36. 10.7326\/0003-4819-155-8-201110180-00009","journal-title":"Ann Intern Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/001316446002000104","article-title":"A coefficient of agreement for nominal scales","volume":"20","author":"Cohen J","year":"1960","unstructured":"Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960, 20:37-46. 10.1177\/001316446002000104","journal-title":"Educ Psychol Meas"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement","volume":"327","author":"Bland JM","year":"1986","unstructured":"Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986, 327:307-10. 10.1016\/S0140-6736(86)90837-8","journal-title":"Lancet"},{"key":"ref20","unstructured":"R. a language and environment for statistical computing. (2025). https:\/\/www.r-project.org\/."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/sim.942","article-title":"A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations","volume":"20","author":"Rutter CM","year":"2001","unstructured":"Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med. 2001, 20:2865-84. 10.1002\/sim.942","journal-title":"Stat Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2005.02.022","article-title":"Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews","volume":"58","author":"Reitsma JB","year":"2005","unstructured":"Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005, 58:982-90. 10.1016\/j.jclinepi.2005.02.022","journal-title":"J Clin Epidemiol"},{"key":"ref23","doi-asserted-by":"crossref","DOI":"10.1214\/aoms\/1177729756","article-title":"Transformations related to the angular and the square root","volume":"21","author":"Freeman MF","year":"1950","unstructured":"Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Stat. 1950, 21:607-11.","journal-title":"Ann Math Stat"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian R","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986, 7:177-88. 10.1016\/0197-2456(86)90046-2","journal-title":"Control Clin Trials"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout J","year":"2014","unstructured":"IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014, 14:25. 10.1186\/1471-2288-14-25","journal-title":"BMC Med Res Methodol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins JP","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003, 327:557-60. 10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger M","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315:629-34. 10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt GH","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008, 336:924-6. 10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-188270","article-title":"Rapid clinical mutation screening for AML using the Genexus platform","volume":"142","author":"Jiwani S","year":"2023","unstructured":"Jiwani S, Radich JP, Saeed M, et al.. Rapid clinical mutation screening for AML using the Genexus platform. Blood. 2023, 142:2288. 10.1182\/blood-2023-188270","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016444","article-title":"FLT3-ITD measurable residual disease from the QuANTUM-First trial","author":"Levis MJ","year":"2025","unstructured":"Levis MJ, Erba HP, Montesinos P, et al.. FLT3-ITD measurable residual disease from the QuANTUM-First trial. Blood Adv. 2025, 10.1182\/bloodadvances.2025016444","journal-title":"Blood Adv"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018015925","article-title":"A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations","volume":"2","author":"Levis MJ","year":"2018","unstructured":"Levis MJ, Perl AE, Altman JK, et al.. A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv. 2018, 2:825-31. 10.1182\/bloodadvances.2018015925","journal-title":"Blood Adv"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2012.08.001","article-title":"Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data","volume":"15","author":"Spencer DH","year":"2013","unstructured":"Spencer DH, Abel HJ, Lockwood CM, et al.. Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data. J Mol Diagn. 2013, 15:81-93. 10.1016\/j.jmoldx.2012.08.001","journal-title":"J Mol Diagn"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4333","article-title":"Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia","volume":"6","author":"Bibault JE","year":"2015","unstructured":"Bibault JE, Figeac M, H\u00e9levaut N, et al.. Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia. Oncotarget. 2015, 6:22812-21. 10.18632\/oncotarget.4333","journal-title":"Oncotarget"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.21955","article-title":"Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations","volume":"51","author":"Thol F","year":"2012","unstructured":"Thol F, K\u00f6lking B, Damm F, et al.. Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. Genes Chromosomes Cancer. 2012, 51:689-95. 10.1002\/gcc.21955","journal-title":"Genes Chromosomes Cancer"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016567","article-title":"Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome","volume":"140","author":"Loo S","year":"2022","unstructured":"Loo S, Dillon R, Ivey A, et al.. Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome. Blood. 2022, 140:2407-11. 10.1182\/blood.2022016567","journal-title":"Blood"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0483-z","article-title":"getITD for FLT3-ITD-based MRD monitoring in AML","volume":"33","author":"Bl\u00e4tte TJ","year":"2019","unstructured":"Bl\u00e4tte TJ, Schmalbrock LK, Skambraks S, et al.. getITD for FLT3-ITD-based MRD monitoring in AML. Leukemia. 2019, 33:2535-9. 10.1038\/s41375-019-0483-z","journal-title":"Leukemia"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/462158-the-analytical-performance-and-inter-laboratory-standardization-of-next-generation-sequencing-ngs-panels-for-genetic-risk-stratification-in-acute-myeloid-leukemia-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T06:10:39Z","timestamp":1770617439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/462158-the-analytical-performance-and-inter-laboratory-standardization-of-next-generation-sequencing-ngs-panels-for-genetic-risk-stratification-in-acute-myeloid-leukemia-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,8]]},"references-count":36,"URL":"https:\/\/doi.org\/10.7759\/cureus.103240","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,8]]}}}